FDA/Industry Dispute On Hypogonadism Drug Efficacy Endpoints To Get Panel Review

Clinical trials should go beyond merely demonstrating maintenance of spermatogenesis, US FDA says, but drug developers assert an increase in serum testosterone levels and/or improvement or maintenance of sperm concentration are appropriate clinical measures to support approval.